Drugs / Anti-thymocyte globuline
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02333838 | May 2015 → May 2018 | myeloid leukemia | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-thymocyte globuline | “IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)” NCT02333838 ↗ |
| Known as | Thymogobuline | “IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)” NCT02333838 ↗ |
| Route | Intravenous | “IV Anti-thymocyte globuline” NCT02333838 ↗ |